India’s generics medicine industry is unlikely to be impacted by President Donald Trump’s move to slash drug prices in the US drastically, said Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA).
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Leave a Comment